Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD5 | P21918 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2442841 | 0.77 | PTGDR2 (0.41) | DRD1DRD3ALDH1A1ADRA1A | |
| SCHEMBL1515856 | 0.76 | PTGDR2 (0.43) | — | |
| SCHEMBL2446792 | 0.76 | PTGDR2 (0.43) | — | |
| SCHEMBL17594282 | 0.74 | SLC6A2 (0.39) | MEN1KMT2AALDH1A1ADRA1A | |
| SCHEMBL28053545 | 0.69 | DRD2 (0.34) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL27549490 | 0.64 | PROKR1 (0.45) | PROKR1ALDH1A1 | |
| SCHEMBL13937420 | 0.62 | RPS6KB1 (0.41) | PTPN11MEN1KMT2AALDH1A1 | |
| SCHEMBL4392361 | 0.62 | KMT2A (0.41) | PROKR1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL28053542 | 0.62 | PROKR1 (0.39) | PROKR1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5748326 | 0.62 | PTGDR2 (0.49) | MEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1847535-A1 | 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | TPH1, HTR1D, HTR1B | DRD2 49/4885DRD1 29/4885DRD4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.